glp-1 agonists for diabetes Receptor as Treatments Type 2 GLP-1 Agonists In Obesity

8 marzo 2023 [citato 30 giugno 2024];14

[DOI] [PubMed] [Google Scholar] 63.Zelniker T.A., Wiviott S.D., Raz I., Im K., Goodrich E.L., Furtado R.H.M., Bonaca M.P., Mosenzon O., Kato E.T., Cahn A., et al

If proven equally effective, they could dramatically expand adoption, especially among patients needle-averse or unwilling to self-inject

doi: 10.1038/nrendo.2017.122

As we noted in a recent GLP1-s white paper, the longterm commercial implications of these actions remain unclear

Given at higher doses than in diabetes treatment, GLP-1 analogues are now routinely licensed for the treatment of obesity, for example high-dose Liraglutide 3 mg daily (43) and Semaglutide 2.4 mg weekly (44)